News & Videos - COLOPLAST NAM. BDK 1

Please see enclosed pdf. Attachment 08032024_trading_in_shares_LRA...

Please see enclosed pdf. Attachment 06032024_trading_in_shares_ASL...

Please see enclosed pdf. Attachment 06032024_trading_in_shares_KVI...

Please see enclosed pdf. Attachment 01032024_trading_in_shares_ARA...

Please see enclosed pdf. Attachment 28022024_trading_in_shares_GL...

Report on transactions of executives and related parties in Coloplast shares and related securities According to the Market Abuse Regulation article 19 Coloplast is obliged to report on the transactions of executives and their related parties in Coloplast shares and related securities. The below transactions concern allocation of share options. For further details, reference is made to Coloplast’s Remuneration Policy. The policy is available on the group website at this address:...

The new transanal irrigation device is designed to help people facing defecation issues or stool leakage. It is estimated that 10-15% of the world’s population are affected by chronic constipation 1 and that 6% struggle with faecal incontinence 2 , both of which can cause physical discomfort and mental distress 3 . Although transanal irrigation treatment can help, the journey to treatment is often challenging with many patients left untreated. For some patients, symptoms are not considered...

Q1 2023/24 Interim financial results, Q1 2023/24 1 October 2023 - 31 December 2023 Coloplast delivered a solid Q1 with 8% organic growth and an EBIT margin 1) of 28%. Reported revenue in DKK grew 8% with 4%-points contribution from Kerecis (underlying growth of around 35%), offset by negative impact from currencies. Organic growth rates by business area: Ostomy Care 8%, Continence Care 8%, Voice and Respiratory Care 7%, Advanced Wound Care 9% (Advanced Wound Dressings 9%) and Interventional...

The company aims to expand its position within advanced wound care by introducing a new silicone foam that will benefit both healthcare professionals and patients. “We are now introducing new innovation to the US market, aiming to grow our presence within the foam dressings segment. We have a great product in our hands, and we have invested significantly in our sales organization to reach the full potential of this launch. I am really excited to get started,” says Kimberly Ditter, Vice...

Friday, 9 February 2024 at 11.00 - 12.00 CET In connection with the publication of Coloplast’s interim financial results for Q1 2023/24, to be released same day around 07.30 am CET, Coloplast will host a conference call to present the financial results and answer questions from investors and financial analysts. A presentation will be available on Coloplast’s website approximately 1 hour before the conference call. The webcast of the conference call will be available during and after the...

Today, 7 December 2023, Coloplast A/S held its Annual General Meeting, at which EY Godkendt Revisionspartnerselskab was elected as Coloplast A/S’ auditors in line with the proposal from the Board of Directors. For further information, please contact Investors and analysts Anders Lonning-Skovgaard Executive Vice President, CFO Tel. +45 4911 1111 Aleksandra Dimovska Senior Director, Investor Relations Tel. +45 4911 1800 / +45 4911 2458 Email: [email protected] Kristine Husted Munk Senior...

Articles of association for Coloplast A/S as adopted at the Annual General Meeting of Coloplast A/S held today, 7 December 2023 are enclosed. For further information, please contact Investors and analysts Anders Lonning-Skovgaard Executive Vice President, CFO Tel. +45 4911 1111 Aleksandra Dimovska Senior Director, Investor Relations Tel. +45 4911 1800 / +45 4911 2458 Email: [email protected] Kristine Husted Munk Senior Manager, Investor Relations Tel. +45 4911 1800 / +45 4911 3266 Email:...

Today, 7 December 2023, Cololast A/S held its Annual General Meeting, at which the following resolutions were adopted: The annual report for the financial year 2022/23 was approved. Distribution of year-end dividend of DKK 16 per share of nominally DKK 1 was approved. In addition to the interim dividend of DKK 5.00 per share of nominally DKK 1 paid out in connection with Coloplast A/S’ half-year result, this brings the total dividend paid for the financial year 2022/23 to DKK 21.00 per share...

The Annual General Meeting of Coloplast A/S will be held on Thursday, 7 December 2023 at 3:30 pm CET at the premises of Coloplast A/S, Holtedam 3 in Humlebæk (the Aage Louis-Hansen Auditorium), Humlebæk, Denmark. The notice of the Annual General Meeting is enclosed. For further information, please contact Investors and analysts Anders Lonning-Skovgaard Executive Vice President, CFO Tel. +45 4911 1111 Aleksandra Dimovska Senior Director, Investor Relations Tel. +45 4911 1800 / +45 4911 2458...

Coloplast, a leading company within intimate healthcare, will invest around 100 million euros in a new manufacturing site in Portugal to support the company’s continued growth. The new manufacturing site will produce Coloplast’s intermittent catheters used by people suffering from urinary retention, such as people with spinal cord injury or spina bifida, who are unable to empty their bladder. With the new site, Coloplast aims to meet the increasing global demand for intermittent catheters,...

FY 2022/23 organic growth of 8% and 28% EBIT margin 1) . Reported revenue in DKK grew 9% to DKK 24,500 million Organic growth rates by business area: Ostomy Care 8%, Continence Care 7%, Voice and Respiratory Care 10% (8 months), Advanced Wound Care 7% (Advanced Wound Dressings 6%), and Interventional Urology 10%. EBIT 1) was DKK 6,845 million, down 1% from last year. The EBIT margin 1,2) was 28% against 31% last year, reflecting inflationary headwind on input costs and an increase in operating...

Announcement of Full-year Financial Results 2022/23 (1 October 2022 - 30 September 2023) Coloplast delivered Q4 organic growth of 8% and 28% EBIT margin 1) . Reported revenue in DKK grew 3% to 6,226 million, impacted by unfavourable development in currencies Organic growth rates by business area: Ostomy Care 9%, Continence Care 6%, Voice and Respiratory Care 13%, Advanced Wound Care 8% (Advanced Wound Dressings 12%), and Interventional Urology 5%. Continued good momentum across regions in...

Coloplast announces financial guidance for the 2023/24 financial year. Organic revenue growth is expected around 8% and the EBIT margin is expected at 27-28%. The assumptions on the financial guidance are laid out below. Organic growth is expected around 8% in constant currencies. The guidance assumes growth across business areas and regions to be largely in line with the Strive25 ambitions, except for China. Chronic Care: Improvement in growth in China, however, China is not expected to return...

Please see enclosed pdf. For more information and calendar invitations for upcoming events, please visit: https://investor.coloplast.com/investor-relations/financial-calendar-and-events/ Kind regards, Investor Relations Coloplast A/S Tel. +45 4911 1800 For further information, please contact Investors and analysts Anders Lonning-Skovgaard Executive Vice President, CFO Tel. +45 4911 1111 Aleksandra Dimovska Senior Director, Investor Relations Tel. +45 4911 1800 / +45 4911 2458 Email:...

Monday, 4 September 2023 at 14.00 – 15.00 CEST In connection with the completion of the acquisition of Kerecis, Coloplast will host a conference call with Fertram Sigurjonsson, Founder and CEO of Kerecis. A presentation will be available on Coloplast’s website before the conference call. The webcast of the conference call will be available during and after the event. Coloplast will be represented by : Kristian Villumsen - President & CEO Anders Lonning-Skovgaard - Executive Vice President,...